Biomarkers in carcinoma of the gallbladder

Bibliography

• Lazcano-Ponce E, Miquel J F, Ferrecio C, et al. Epidemiology and molecular pathology of gallbladder cance. CA Cancer J Clin 2001;51:349-64
   PubMed Web of Science ®Google Scholar
• Abi-Rached B, Neugut AI. Diagnostic and management issues in gallbladder carcinoma. Oncology (Huntingt) 1995;9:19-24; discussion 24, 27, 30
   PubMedGoogle Scholar
• Dhir V, Mohandas KM. Epidemiology of digestive tract cancers in India IV. Gallbladder and Pancreas. Indian J Gastroenterol 1999;18:24-8
   PubMedGoogle Scholar
• Kaushik SP, Kapoor VK, Haribhakti SP. Carcinoma gallbladder. GI Surg Ann 1997;4:87-101
   Google Scholar
• Wanebo HJ, Michael PV. Carcinoma gallbladder. J Surg Oncol 1993;3(Suppl):134-9
   Google Scholar
• Tazuma S, Kajiyama G. Carcinogenesis of malignant lesions of the gallbladder. the impact of chronic inflammation and gallstones. Langenbecks Arch Surg 2001;386:224-9
   PubMed Web of Science ®Google Scholar
• Chu TM. Biochemical markers for human cancer, In: Seifert G, editor, Morphological tumors markers, general aspects and diagnostic relevance. Springer: Verlag; 1987. p. 19-42
   Google Scholar
• Harnden DG. Human tumor markers. Biological basis and clinical relevance. J Roy Soc Med 1985;78:1071-72
   Google Scholar
• Virji MA, Mercer DW, Herberman RB. Tumor Markers and their measurements. Pathol Res Pract 1988;183:95-9
   PubMed Web of Science ®Google Scholar
• Bates SE, Longo DL. Use of serum tumor markers in cancer diagnosis and management. Semin Oncol 1987;14:102-38
   PubMed Web of Science ®Google Scholar
• Shukla VK, Gurubachan, Sharma D, et al. Diagnostic value of serum CA 242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder. Trop Gastroenterol 2006;27(4):160-5
   PubMedGoogle Scholar
• M Enjoji a, Yamaguchi b K, Nakamuta M, et al. Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases. Dig Liver Dis 2004;36:622-7
   PubMedGoogle Scholar
• Atkinson BF, Ernst CS, Herlyn M, et al. Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res 1982;42:4820-3
   PubMed Web of Science ®Google Scholar
• Dietel M, Arps H, Klapdor R, et al. Antigen detection by the monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue and patients sera. J Cancer Res Clin Oncol 1986;111:257-65
   PubMed Web of Science ®Google Scholar
• Haglund C, Lindgren J, Roberts P, et al. Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA 19-9. Int J Cancer 1986;38:841-6
   PubMed Web of Science ®Google Scholar
• Haglund C, Lindgren J, Roberts P, et al. Gastrointestinal cancer-associated antigen CA 19-9 in histological specimes of pancreatic tumours and pancreatitis. Br J Cancer 1986;53:189-95
   PubMed Web of Science ®Google Scholar
• Nishida K, Miyagawa H, Yoshikawa T, et al. Concentration and localization of carbohydrate antigen 19-9 in tissues of pancreatic cancer. Oncology 1988;45:166-71
   PubMed Web of Science ®Google Scholar
• Schwenk J, Makowitzky J. Tissue expression of the cancer associated antigens CA 19-9 and CA-50 in chronic pancreatitis and pancreatic carcinoma. Int J Pancreatol 1989;5:85-98
   PubMedGoogle Scholar
• Malati T. Tumor markers. An overview. Indian J Clin Biochem 2007;22(2):17-31
   PubMed Web of Science ®Google Scholar
• Akdogan M, Parlak E, Kayhan B, et al. Are serum and biliary carcinoembryonic antigen and carbohydrate antigenl9-9 determinations reliable for differentiation between benign and malignant biliary disease. Turk J Gastroenterol 2003;14(3):181-4
   PubMedGoogle Scholar
• Redaelli CA, Büchler MW, Schilling MK, et al. High coincidence of Mirizzi syndrome and gallbladder carcinoma. Surgery 1997;121(1):58-63
   PubMed Web of Science ®Google Scholar
• Bergquist A, Glaumann H, Persson B, et al. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. A case-control study. Hepatology 1998;27(2):311-6
   PubMed Web of Science ®Google Scholar
• Rumalla A, Petersen BT. Diagnosis and therapy of biliary tract malignancy. Semin Gastrointest Dis 2000;11(3):168-73
   PubMedGoogle Scholar
• Noshiro H, Chijiiwa K, Yamaguchi K, et al. Factors affecting surgical outcome for gallbladder carcinoma. Hepatogastroenterology 2003;50(52):939-44
   PubMed Web of Science ®Google Scholar
• Tasaki K, Yamamoto H, Watanabe K, et al. Successful treatment of lymph node metastases recurring from gallbladder cancer. J Hepatobiliary Pancreat Surg 2003;10(1):113-7
   PubMedGoogle Scholar
• Maruiwa M, Yano H, Kataoka A, et al. Heterotransplantation of an alphafetoprotein-producing human gallbladder carcinoma into nude mice. Acta Pathol Jpn 1988;38:501-13
   PubMedGoogle Scholar
• Harmenberg U, Wahren B, Wiechel KL. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract. Cancer Res 1988;48:1985-8
   PubMed Web of Science ®Google Scholar
• Kimura W, Muto T, Esaki Y. Incidence and Pathogenesis of villous tumors of the gallbladder and their relation to cancer. J Gastroenterol 1994;29:61-5
   PubMed Web of Science ®Google Scholar
• Sasaki R. Immunohistochemical study of cancer-associated carbohydrate antigens in carcinoma of the biliary tract. Nippon Geka Gakkai Zasshi 1989;90:1976-88
   PubMedGoogle Scholar
• Roa I, Arya JC, Shirasch T, et al. Gallbladder cancer. Immunohistochemical expression of CA 19-9, epithelial membrane antigen, dupin-2 and CEA. Rev Med Chil 1992;120:1218-26
   PubMed Web of Science ®Google Scholar
• Pingitore R, Bonucci M, Bigini D, et al. Chronic calculus choecystitis. Elementary and dysplastic lesions, echographic correlations and Immunohistochemical approach. Pathologica 1992;84:171-85
   PubMedGoogle Scholar
• Stefanovic D, Novakovic R, Perisic-Savic M, et al. The evaluation of tumor markers levels in determination of surgical procedure in patients with gallbladder carcinoma. Med Pregl 1993;46(Suppl 1):58-9
   PubMedGoogle Scholar
• Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999;5:938-42
   PubMed Web of Science ®Google Scholar
• Enjoji M, Nakashima M, Nishi H, et al. The tumor-associated antigen, RCAS1, can be expressed in immune-mediated diseases as well as in carcinomas of the biliary tract. J Hepatol 2002;36:786-92
   PubMed Web of Science ®Google Scholar
• Oshikiri T, Hida Y, Miyamoto M, et al. RCAS1 expression as a prognostic factor after curative surgery for extrahepatic bile duct cancer. Br J Cancer 2001;85,1922-7
   PubMed Web of Science ®Google Scholar
• Bast RC Jr. Freeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7
   PubMed Web of Science ®Google Scholar
• O'Brien TJ, Raymond LM, Bannon GA. New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope. Am J Obstet Gynecol 1991;165:1857-64
   PubMed Web of Science ®Google Scholar
• Davis HM, Zurawski VR, Bast RC, et al. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res 1986;46:6143-8
   PubMed Web of Science ®Google Scholar
• Magnani J, Nilsson B, Brockhous M, et al. The Antigen of a Tumor Specific Monoclonal Antibody is a Ganglioside containing sialylated lacto-N-fucopentaose II. Federation Proceedings 1982;41:898
   Google Scholar
• Chaube A, Tewari M, Singh U, et al. CA 125. A potential tumor marker for gallbladder cancer. J Surg Oncol 2006;93(8):665-9
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Shering S, Sherry F, et al. CA15.3. a prognostic marker in breast cancer. Int J Biol Markers 2000;1:330-3
   Google Scholar
• Nalini R, Delphine W, Silvia CR, et al. Usefulness of serum CA15.3 and Histopathological prognostic indices in breast cancer. Ind J Clin Biochem 2005;20:165-8
   Google Scholar
• Thriveni K, Krishnamoorthy L, Ramaswamy G. Correlation study of carcino embryonic antigen & cancer antigen 15.3 in pretreated female breast cancer patient. Ind J Clin Biochem 2007;22:57-60
   Google Scholar
• Lindholm L, Holmgren J, Svennerholm L, et al. Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immun 1983;71:178-81
   PubMedGoogle Scholar
• Johansson C, Nilsson O, Bäckström D. Novel epitopes on the CA50-carrying antigen. chemical and immunochemical studies. Tumour Biol 1991;12:159-70
   PubMed Web of Science ®Google Scholar
• Johansson C, Nilsson O, Lindholm L. Comparison of serological expression of different epitopes on the CA50 carrying antigen CanAg. Int J Cancer 1991;48:757-63
   PubMed Web of Science ®Google Scholar
• Pasanen P, Eskelinen M, Partanen K, et al. Multivariate analysis of six serum tumour markers(CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. Anticancer Res 1995;15:2731-8
   PubMed Web of Science ®Google Scholar
• Brockmann J, Emparan C, Hernandez CA, et al. Gallbladder bile tumor marker quantification for detection of pancreatico-biliary malignancies. Anticancer Res 2000;20:4941-7
   PubMed Web of Science ®Google Scholar
• Bordes M, Michiels R, Martin F. Detection by immunofluorescence of carcinoembryonic antigen in colonic carcinoma, other malignant and benign tumor and non-cancerous tissues. Digestion 1973;9:106-15
   PubMed Web of Science ®Google Scholar
• Isaacson P. The demonstration of carcinoembryonic antigen (CEA) in ulcerative colitis. Gut 1976;17:561-7
   PubMed Web of Science ®Google Scholar
• O'Brien MJ, Zamcheck N, Burke B, et al. Immunocytochemical localization of carcinoembryonic antigen in benign and malignant colorectal tissues. Assessment of diagnostic value. Am J Clin Pathol 1981;75:283-90
   PubMed Web of Science ®Google Scholar
• Strom BL, Uiopoulos D, Atkinson B, et al. Pathophysiology of tumor progression in human gallbladder. Flow cytometry CEA and CA 19-9 levels in bile and serum in different stages of gallbladder diseases. J Natl Cancer Inst 1989;81:1575-80
   PubMed Web of Science ®Google Scholar
• Okami J, Dohno K, Sakon M, et al. Genetic detection for micrometastasis in lymph node of biliary tract carcinoma. Clin Cancer Res 2000;6: 2326-32
   PubMed Web of Science ®Google Scholar
• Kanthan R, Radhi JM, Kanthan SC. Gallbladder carcinomas. An immunoprognostic evaluation on p53, Bcl-2, CEA and alpha fetoprotein. Can J Gastroenterol 2000;14:181-4
   PubMed Web of Science ®Google Scholar
• Dowaki S, Kijima H, Kashiwagi H, et al. CEA immunohistochemical localization is correlated with growth and metastasis of human gallbladder carcinoma. Int J Oncol 2000;16(1):49-53
   PubMed Web of Science ®Google Scholar
• Vij U, Baskaran V. Value of serum CEA and AFP in the diagnosis and prognosis of carcinomagallbladder. Trop Gastroenterol 2001;22(4):227-9
   PubMedGoogle Scholar
• Matsuda M, Shimizu Y, Chikamatsu E, et al. Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer. Nippon Geka Gakkai Zasshi 1991;92:716-21
   PubMedGoogle Scholar
• Maxwell P, Davis RI, Sloan JM. Carcinoembryonic antigen (CEA) in benign and malignant epithelium of the gall bladder, extrahepatic bile ducts, and ampulla of Vater. J Pathol 1993;170:73-6
   PubMed Web of Science ®Google Scholar
• Albores-Saavedra J, Nadji M, Morales AR, et al. Carcinoembryonic antigen in normal, preneoplastic and neoplastic gallbladder epithelium. Cancer 1983;52(6):1069-72
   PubMed Web of Science ®Google Scholar
• Choi YL, Xuan YH, Shin YK, et al. An immunohistochemical study of the expression of adhesion molecules in gallbladder lesions. J Histochem Cytochem 2004;52(5):591-601
   PubMed Web of Science ®Google Scholar
• Egawa N, Tu Y, Kamisawa T, et al. A comparative clinical study of gallbladder tubular adenocarcinoma according to the grade of differentiation. J Gastroenterol 2004;39(10):975-80
   PubMed Web of Science ®Google Scholar
• Akdogan M, Parlak E, Kayhan B, et al. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease? Turk J Gastroenterol 2003;14(3):181-4. Erratum in: Turk J Gastroenterol 2004;15(2):122
   Google Scholar
• Akiyama H, Yamamoto M, Sumiyoshi H, et al. Carcinoembryonic antigen (CEA) in gallbladder bile and mucosa in cholecystolithiasis. Acta Chir Scand 1986;152:509-13
   PubMedGoogle Scholar
• Lurie BB, Loewenstein MS, Zamcheck N. Elevated carcinoembryonic antigen levels and biliary tract obstruction. JAMA 1975;233(4):326-30
   PubMed Web of Science ®Google Scholar
• Kashiwagi H, Kijima H, Dowaki S, et al. MUC1 and MUC2 expression in human gallbladder carcinoma. A clinicopathological study and relationship with prognosis. Oncol Rep 2001;8:485-9
   PubMed Web of Science ®Google Scholar
• Kashiwagi H, Kijima H, Dowaki S, et al. DF3 expression in human gallbladder carcinoma. Significance for lymphatic invasion. Int J Oncol 2000;16:455-9
   PubMed Web of Science ®Google Scholar
• Kawamoto T, Shoda J, Irimura T, et al. Expression of MUC1 mucins in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage? carcinoma of the gallbladder. Clin Cancer Res 2001;7:1333-42
   PubMed Web of Science ®Google Scholar
• Chang HJ, Kim SW, Lee BL, et al. Phenotypic alterations of mucins and cytokeratins during gallbladdercarcinogenesis. Pathol Int 2004;54(8):576-84
   PubMed Web of Science ®Google Scholar
• Isozaki H, Okajimo K, Hara H, et al. Proliferating nuclear antigen expression in the gallbladder with pancreatobiliary maljunction. J Surg Oncol 1997;65:46-9
   PubMed Web of Science ®Google Scholar
• Hanada K, Itoh M, Fujii K, et al. Expression of the proliferative cell nuclear antigen (PCNA) in adenocarcinoma of the gallbladder, and its relationship to prognosis. Scand J Clin Lab Invest 1995;55:377-82
   PubMed Web of Science ®Google Scholar
• Hanada K, Itoh M, Fujii K, et al. Pathology and cellular kinetics of gallbladder with an anomalous junction of the pancreatico-biliary duct. Am J Gastroenterol 1996;91:1007-11
   PubMed Web of Science ®Google Scholar
• Lee CS. Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and Ki-67 antigen immunoreactivity in insitu and invasive carcinomas of the extrahepatic biliary tree. Cancer 1996;78:1881-7
   PubMed Web of Science ®Google Scholar
• Quing D, xia L, Zhang X. The expressions of proliferating cell nuclear antigen(PCNA) in primary gallbladder carcinoma and its significance. Zhonghua Wai Ke Za Zhi 1995;33:102-4
   PubMedGoogle Scholar
• Wistuba II, Sugio K, Hung J, et al. Allele specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 1995;55:2511-5
   PubMed Web of Science ®Google Scholar
• Sasatomi E, Tokunaga O, Miyazaki K. Spontaneous Apoptosis in gallbladder carcinoma. relationship with clinicopathlogic factors, expression of E-cadherin, bcl2 protooncogene, and p53 oncosuppressor gene. Cancer 1993;78:2101-10
   Google Scholar
• Knudson AG Jr. The ninth Gordon Hamilton-Fairley memorial lecture. Hereditary cancers: clues to mechanisms of carcinogenesis. Br J Cancer 1989;59:661-6
   PubMed Web of Science ®Google Scholar
• Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31
   PubMed Web of Science ®Google Scholar
• Greenblatt MS, Bennett WP, Hollatein M, et al. Mutations in the p53 tumor supressor gene. clue to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78
   PubMed Web of Science ®Google Scholar
• Harris CC. p53 Tumor suppressor gene from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 1996;17:1187-98
   PubMed Web of Science ®Google Scholar
• Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC) 1994;264:436-40
   PubMed Web of Science ®Google Scholar
• Wistuba I, Gazdar A F, Sugio K, et al. Abnormalities of p53 and K-ras gene in the pathogenesis of endemic gallbladder carcinoma (GBC) in Chile [abstract]. Lab Invest 1995;72:70A
   PubMed Web of Science ®Google Scholar
• Itoi T, Watanabe H, Yoshida M, et al. Correlation of p53 protein expression with gene mutation in gallbladder carcinomas. Pathol Int 1997;47:525-30
   PubMed Web of Science ®Google Scholar
• Cunningham J, Lust JA, Schaid DJ, et al. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 1992;52:1974-80
   PubMed Web of Science ®Google Scholar
• Wagata T, Shibagaki I, Imamura M, et al. Loss of17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res 1993;53:846-50
   PubMed Web of Science ®Google Scholar
• Hidaka E, Yanagisawa A, Sakai Y, et al. Losses of heterozygosity on chromosomes 17p and 9p/18q my play important roles in early and advanced phases of gallbladder carcinogenesis. J Cancer Res Clin Oncol 1999;125:439-43
   PubMed Web of Science ®Google Scholar
• Ajiki T, Onoyama H, Yamamoto M, et al. p53 protein expressoin and prognosis in gallbladder carcinoma and pemalignant lesion. Hepatogastroenterology 1996;43:521-6
   PubMed Web of Science ®Google Scholar
• Billo P, Marchegiani C, Capella C, et al. Expression of p53 in gallbladder carcinoma and in dysplastic and metaplastic lesions of the surrounding mucosa. Pathologica 2000;92:249-56
   PubMedGoogle Scholar
• Misra S, Chaturvedi A, Goel MM, et al. Overexpression of p53 protein in gallbladder carcinoma in North India. Eur J Surg Oncol 2000;26:164-7
   PubMedGoogle Scholar
• Mauricio Moreno, Fernando Pimentel, Adi F Gazdar, et al. TP53 abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma. Ann Hepatol 2005;4(3):192-9
   PubMedGoogle Scholar
• Lee SC, Pirdas A. p53 protein immunoreactivity in cancers of the gallbladder, extrehepatic bile ducts and ampulla of Vater. Pathology 1995;27:117-20
   PubMed Web of Science ®Google Scholar
• Kamb A, Gruãs NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC) 1994;264:436-40
   PubMed Web of Science ®Google Scholar
• Okamoto A, Demetrick D J, Spillare, et al. Mutations and altered expression of pl6INK4 in human cancer. Proc Natl Acad Sci USA 1994;91:11045-9
   PubMed Web of Science ®Google Scholar
• Yoshida S, Todoroki T,Ichikawa Y, et al. Mutations of p16ink4/CDKN2 and p15ink4b/MTS2 genes in biliary tract cancers. Cancer Res 1995;55:2756-60
   PubMed Web of Science ®Google Scholar
• Barbacid M. ras genes. Ann Rev Biochem 1987;56:779-827
   PubMed Web of Science ®Google Scholar
• Bos JL. The ras gene family and human carcinogenesis. Mutat Res 1988;195:255-71
   PubMed Web of Science ®Google Scholar
• Lee JC, Lin PW, Lin YJ, et al. Analysis of K-ras gene mutations in periampullary cancers, gallbladder cancers and cholangiocarcinomas from paraffin-embedded tissue sections. J Formos Med Assoc 1995;94:719-23
   PubMed Web of Science ®Google Scholar
• Ajiki T, Fujimori T, Onoyama H, et al. K-ras gene mutation in gallbladder carcinomas and dysplasia. Gut 1996;38:426-9
   PubMed Web of Science ®Google Scholar
• Hanada K, Itoh M, Fujii K, et al. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 1996;77:452-8
   PubMed Web of Science ®Google Scholar
• Hanada K, Tsuchida A, Iwao T, et al. Gene mutations of K-ras in in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliry duct. Am J Gastroenterol 1999;94:1638-42
   PubMed Web of Science ®Google Scholar
• Fearson ER, Cho KR, Nigro JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990;247:49-56
   PubMed Web of Science ®Google Scholar
• Wistuba II, Tang M, Maitra A, et al. Genome-wide allelotyping analysis reveals multiple sites of allelic loss in gallbladder carcinoma. Cancer Res 2001;61(9):3795-800
   PubMed Web of Science ®Google Scholar
• Yoshida T, Sugai T, Habano W, et al. Microsatellite instability in gallbladder carcinoma. two independent genetic pathways of gallbladder carcinogenesis. J Gastroenterol 2000;35(10):768-74
   PubMed Web of Science ®Google Scholar
• Matsuo K, Kuroki T, Kitaoka F, et al. Loss of heterozygosity of chromosome 16q in gallbladder carcinoma. J Surg Res 2002;102(2):133-6
   PubMed Web of Science ®Google Scholar
• Tanaka H, Shimada Y, Harada H, et al. Methylation of the 50 CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res 1998;58:3429-34
   PubMed Web of Science ®Google Scholar
• Zochbauer-Muller S, Fong KM, Maitra A, et al. 50 CpG island methylation of the FHIT gene is with loss of gene expression in lung and breast cancer. Cancer Res 2001;61:3581-5
   PubMed Web of Science ®Google Scholar
• Wistuba II, Ashfaq R, Maitra A, et al. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma. Am J Pathol 2002;160:2073-9
   PubMed Web of Science ®Google Scholar
• Koda M, Yashima K, Kawaguchi K, et al. Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma. Cancer Lett 2003;199:131-8
   PubMed Web of Science ®Google Scholar
• Riquelme E, Tang M, Baez S, et al. Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma. Cancer Lett 2007;250(1):100-6
   PubMed Web of Science ®Google Scholar
• Yamaguchi A, Zhang M, Goi T, et al. Expression of variant CD44 containing variant exon v8-10 in gallbladder cancer. Oncol Rep 2000;7:541-4
   PubMed Web of Science ®Google Scholar
• Prall F, Nollau P, Neumaier M, et al. CD 66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues. J Histochem Cytochem 1996;44:35-41
   PubMed Web of Science ®Google Scholar
• Roa I, Villaseca M, Araya J, et al. CD44 (HCAM) expression in subserous gallbladder carcinoma. Rev Med Chil 2001;129:727-34
   PubMed Web of Science ®Google Scholar
• Yanagisawa N, Mikami T, Mitomi H, et al. CD44 variant overexpression in gallbladder carcinoma associated with tumor dedifferentiation. Cancer 2001;91:408-16
   PubMed Web of Science ®Google Scholar
• Furihata M, Ono Y, Ichikawa K, et al. Prognostic significance of CD83 positive, mature dendritic cells in the gallbladder carcinoma. Oncol Rep 2005;14(2):353-6
   PubMed Web of Science ®Google Scholar
• Boudny V, Murakami Y, Nakano S, et al. Expression of activated c-erb-B-2 oncogene induces sensitivity to cisplatin in human gallbladder adenocarcinoma cells. Anticancer Res 1996;19:5203-6
   Google Scholar
• Su WE, Shiesh SC, Liu HS, et al. Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders. Dig Dis Sci 2001;46:1387-92
   PubMed Web of Science ®Google Scholar
• Seitz G, Thelisinger B, Tomasetto G, et al. Breast cancer-associated protein pS2 expressio in tumors of he biliary tract. AM J Gastroenterol 1991;86:1491-4
   PubMed Web of Science ®Google Scholar
• Gorunoval L, Parada LA, Limon J, et al. Nonrandom chromosomal aberrations and cytogenetic heterogeneity in gallbladder carcinomas. Genes Chromosomes Cancer 1999;26:312-21
   PubMed Web of Science ®Google Scholar
• Kanoh K, Shimura T, Tsutsumi S, et al. Significance of contracted cholecystitis lesions as high risk for gallbladder carcinogenesis. Cancer Lett 2001;169:7-14
   PubMed Web of Science ®Google Scholar
• Ghosh M, Kawamoto T, Koike N, et al. Cyclooxygenase expression in the gallbladder. Int J Mol Med 2000;6:527-32
   PubMed Web of Science ®Google Scholar
• Kawamoto T, Shoda J, Asano T, et al. Expression of cyclooxygenase-2 in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Int J Cancer 2002;98(3):427-34
   PubMed Web of Science ®Google Scholar
• Itoi T, Watanabe H, Ajioka Y, et al. APC, K ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gallbladder suggest two genetic pathways in gallbladder carcinogenesis. Pathol Int 1996;46:30-7
   Google Scholar
• Yoshida T, Sugai T, Habano W, et al. Microstellite instability in gallbladder carcinoma. two independent genetic pathways of gallbladder carcinogenesis. J Gastroenterol 2000;35:768-74
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Haga M, Takagi S, et al. HLA antigen in cancer of the gallbladder. Tohoku J Exp Med 1990;161:69-71
   PubMed Web of Science ®Google Scholar
• Tamiolakis D, Simopoulos C, Kotini A, et al. Prognostic significance of HLA-DR antigen in dysplasia, carcinoma in situ and invasive carcinoma of the gallbladder. East Afr Med J 2003;80(11):554-8
   PubMedGoogle Scholar
• Yamamoto S, Kitadai, Tsuchida A, et al. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human gallbladder lesions. Eur J Cancer 2000;36:257-63
   PubMed Web of Science ®Google Scholar
• Okita S, Kondoh S, Shiraishi K, et al. Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer. Int J Oncol 1998;12:1013-8
   PubMed Web of Science ®Google Scholar
• Quan ZW, Wu K, Wang J, et al. Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg 2001;193: 380-3
   PubMed Web of Science ®Google Scholar
• Pandey M, Pathak AK, Singh S, et al. Carcinoma of the gallbladder. A retrospective review of 99 cases. Dig Dis Sci 2001;46:1145-51
   PubMed Web of Science ®Google Scholar
• Piehler JM, Crichlow RW. Primary carcinoma of the gallbladder. A collective review. Surg Gynaecol Obstet 1978;147:929-42
   Google Scholar
• Shukla VK, Khandelwal C, Roy S, et al. Primary carcinoma of the gallbladder. A review of 16 years period at University Hospital. J Surg Oncol Diehl AK. Gall stone size and the risk of gallbladder cancer. J Am Med Asso 1983;250:2323-6
   Web of Science ®Google Scholar
• Diehl AK. Gall stone size and the risk of gallbladder cancer. J Am Med Asso 1983;250:2323-6
   PubMed Web of Science ®Google Scholar
• Pandey M, Shukla VK. Gallbladder Cancer. New Delhi. Jaypee Brothers Med Pub (P) Ltd; 2004
   Google Scholar
• De AX, Riedeman JP, Roa I, et al. CAA 19-9 and carcinoembryonic antigen in gallbladder cancer. Rev Med Chil 1996;124:11-20
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim MH, Myung SJ, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer. analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999;94:1941-6
   PubMed Web of Science ®Google Scholar
• Ohta T, Nagakawa T, Fonseca L, et al. Stromal distribution of CA 19-9 as a predictor of lymph node metastases in gallbladder cancer without serosal invasion. Oncology 1994;51:238-43
   PubMed Web of Science ®Google Scholar
• Ono T, Komatsu M, Hoshino T, et al. Alpha-fetoprotein, carcinoembryonic antigen, and carbohydrate antigen 19-9-producing gallbladder cancer. J Gastroenterol 1996;31:742-6.1985; 28:32-5
   PubMed Web of Science ®Google Scholar
• Ritts RE Jr, Nagorney DM, Jacobsen DJ, et al. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas 1994;9:707-16
   PubMed Web of Science ®Google Scholar
• Roa I, Araya JC, Shiraisch T, et al. Gallbladder cancer. immunohistochemical expression of CA-19-9, epithelial membrane antigen, dupan-2 and carcinoembryonic antigen. Rev Med Chil 1992;120:1218-26
   PubMed Web of Science ®Google Scholar
• Tanigawa N. Gallbladder carcinoma producing CEA, AFP, CA19-9, sialyl SSEA and CSF. Ryoikibetsu Shokogun Shirizu 1996;9:237-9
   PubMedGoogle Scholar
• Ghosh M, Kamma H, Kawamoto T, et al. MUC 1 core protein as a marker of gallbladder malignancy. Eur J Surg Oncol 2005;31:891-6
   PubMed Web of Science ®Google Scholar
• Kashiwagi H, Kijima H, Dowaki S, et al. MUC1 and MUC2 expression in human gallbladder carcinoma. a clinicopathological study and relationship with prognosis. Oncol Rep 2001;8:485-9
   PubMed Web of Science ®Google Scholar
• Kawamoto T, Shoda J, Miyahara N, et al. Expression of MUC1 recognized by a monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of carcinoma of the gallbladder. Clin Exp Metastasis 2004;21:353-62
   PubMed Web of Science ®Google Scholar
• Wongkham S, Sheehan JK, Boonla C, et al. Serum MUC5AC mucin as a potential marker for cholangiocarcinoma. Cancer Lett 2003;195:93-9
   PubMed Web of Science ®Google Scholar
• Yamato T, Sasaki M, Watanabe Y, et al. Expression of MUC1 and MUC2 mucin core proteins and their messenger RNA in gall bladder carcinoma. An immunohistochemical and in situ hybridization study. J Pathol 1999;188:30-7
   PubMed Web of Science ®Google Scholar
• Fan YZ, Fu JY, Zhao ZM, et al. Influence of norcantharidin on proliferation, proliferation-related gene proteins proliferating cell nuclear antigen and Ki-67 of human gallbladder carcinoma GBC-SD cells. Hepatobiliary Pancreat Dis Int 2004;3:603-7
   PubMedGoogle Scholar
• Shrestha ML, Miyake H, Kikutsuji T, et al. Prognostic significance of Ki-67 and p53 antigen expression in carcinomas of bile duct and gallbladder. J Med Invest 1998;45:95-102
   PubMedGoogle Scholar
• Takei K, Watanabe H, Itoi T, et al. p53 and Ki-67 immunoreactivity and nuclear morphometry of ‘carcinoma-in-adenoma’ and adenoma of the gall-bladder. Pathol Int 1996;46:908-17
   PubMed Web of Science ®Google Scholar
• Takei K, Watanabe H, Itoi T, et al. p53 and Ki-67 immunoreactivity and nuclear morphometry of ‘carcinoma-in-adenoma’ and adenoma of the gall-bladder. Pathol Int 1996;46:426-35
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Fujii K, Kitadai Y, et al. Expression of vascular endothelial growth factor in human gallbladder lesions. Oncol Rep 1998;5:1065-9
   PubMed Web of Science ®Google Scholar
• Chaube A, Tewari M, Garbyal RS, et al. Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients manuscript id. 8962091628764582. BMC Cancer 2006;6:126
   PubMedGoogle Scholar
• Kalekou H, Miliaras D. Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma. J Gastroenterol Hepatol 2004;19:812-8
   PubMed Web of Science ®Google Scholar
• Koda M, Yashima K, Kawaguchi K, et al. Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma. Cancer Lett 2003;199:131-8
   PubMed Web of Science ®Google Scholar
• Oohashi Y, Watanabe H, Ajioka Y, et al. p53 immunostaining distinguishes malignant from benign lesions of the gall-bladder. Pathol Int 1995;45:58-65
   PubMed Web of Science ®Google Scholar
• Puhalla H, Kandioler D, Ludwig C, et al. p53 analysis in gallbladder cancer. comparison of gene analysis versus immunohistochemistry. Anticancer Res 2004;24:1201-6
   PubMed Web of Science ®Google Scholar
• Puhalla H, Wrba F, Kandioler D, et al. Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer. Anticancer Res 2007;27:1679-84
   PubMed Web of Science ®Google Scholar
• Tian Y, Ding RY, Zhi YH, et al. Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. World J Gastroenterol 2006;12:415-9
   PubMed Web of Science ®Google Scholar
• Xuan YH, Choi YL, Shin YK, et al. An immunohistochemical study of the expression of cell-cycle-regulated proteins p53, cyclin D1, RB, p27, Ki67 and MSH2 in gallbladder carcinoma and its precursor lesions. Histol Histopathol 2005;20:59-66
   PubMed Web of Science ®Google Scholar
• Yanagisawa N, Mikami T, Koike M, et al. Enhanced cell kinetics, p53 accumulation and high p21WAF1 expression in chronic cholecystitis. comparison with background mucosa of gallbladder carcinomas. Histopathology 2000;36:54-61
   PubMed Web of Science ®Google Scholar
• Ichikawa Y, Kamiyama M, Sekido H, et al. Telomerase activity and Bcl-2 expression in gallbladders of pancreaticobiliary maljunction patients. a preliminary study. J Hepatobiliary Pancreat Surg 2004;11:34-9
   PubMedGoogle Scholar
• Mikami T, Yanagisawa N, Baba H, et al. Association of Bcl-2 protein expression with gallbladder carcinoma differentiation and progression and its relation to apoptosis. Cancer 1999;85:318-25
   PubMed Web of Science ®Google Scholar
• Chow NH, Huang SM, Chan SH, et al. Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. Anticancer Res 1995;15:1055-9
   PubMed Web of Science ®Google Scholar
• Kiguchi K, Carbajal S, Chan K, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 2001;61:6971-6
   PubMed Web of Science ®Google Scholar
• Matsuyama S, Kitajima Y, Sumi K, et al. Gallbladder cancers rarely overexpress HER-2/neu, demonstrated by Hercep test. Oncol Rep 2004;11:815-9
   PubMed Web of Science ®Google Scholar
• Su WC, Shiesh SC, Liu HS, et al. Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders. Dig Dis Sci 2001;46:1387-92
   PubMed Web of Science ®Google Scholar
• Legan M, Luzar B, Ferlan-Marolt V, et al. Cyclooxygenase-2 expression determines neo-angiogenesis in gallbladder carcinomas. Bosn J Basic Med Sci 2006;6:58-63
   PubMedGoogle Scholar